TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07280832: Open-Label, Multicenter Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of JMT108 Injection in Participants With Unresectable or Metastatic Melanoma and Urinary Tract Tumors

Sponsor: Shanghai JMT-Bio Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 500 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT07280832 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07280832 Rescue Dossier →